gdc
PSSGuide_2021
Skin Cancer

Drugs for Skin Cancer/Merkel-Cell Carcinoma

Here are the drugs and financial support services available to patients receiving treatment for Skin Cancer/Merkel-Cell Carcinoma.

Bavencio (avelumab)

Drug company: EMD Serono
844-826-8371

Bavencio is a PD-L1 inhibitor used for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel-cell carcinoma, a type of skin cancer.

EMD Serono offers 2 financial assistance programs for patients using Bavencio:

CoverOne Co-Pay Assistance Program

Through this program, patients with private insurance will be responsible for a $0 copay at participating medical facilities and pharmacies, and may be eligible for copay assistance up to a maximum of $30,000 per year.

CoverOne Patient Assistance Program

This program provides Bavencio at no charge for patients who meet certain income, insurance, and residency eligibility criteria.

Erivedge (vismodegib) Capsules

Drug company: Genentech
866-422-2377

Erivedge is a hedgehog pathway inhibitor used for the treatment of patients with metastatic or locally advanced basal-cell carcinoma, a type of skin cancer.

Genentech Oncology offers 2 financial assistance programs for patients using Erivedge:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Erivedge, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Erivedge free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Erivedge is also provided free for patients who are unable to afford their out-ofpocket costs and cannot find other financial assistance.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of patients with recurrent locally advanced or metastatic Merkel-cell carcinoma, a type of skin cancer. Keytruda is also used for the treatment of patients with recurrent or metastatic cutaneous squamous-cell carcinoma (a type of skin cancer) that cannot be cured by surgery or radiation.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $63,800 or less for individuals, $86,200 or less for a couple, or $131,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Libtayo (cemiplimab-rwlc)

Drug company: Regeneron/Sanofi Genzyme
877-542-8296

Libtayo is a PD-1 inhibitor used for the treatment of patients with metastatic cutaneous squamous-cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery or radiation as a cure.

Regeneron and Sanofi Genzyme offer 2 financial assistance programs for patients who have been prescribed Libtayo:

Libtayo Surround Commercial Copay Program

Eligible patients who have private insurance may pay $0 for Libtayo, including copay, co-insurance, and insurance deductibles, with maximum assistance of $25,000 annually.

Libtayo Surround Patient Assistance Program

Patients who meet this program’s income requirements may receive Libtayo at no cost if they are uninsured, underinsured, or have Medicare Part B coverage with no supplemental insurance. To qualify for this program, patients must have an annual gross household income that does not exceed the greater of $100,000 or 500% of the federal poverty level.

Odomzo (sonidegib) Capsules

Drug company: Sun Pharma
844-563-6696

Odomzo is a hedgehog pathway inhibitor used for the treatment of adults with locally advanced basal-cell carcinoma that has relapsed after surgery or radiation therapy, or in patients not candidates for surgery or radiation therapy.

Sun Pharma provides 2 financial assistance programs for patients using Odomzo:

Odomzo Copay Program

Patients with private insurance who are eligible for this program will pay as little as $10 per month for a prescription of Odomzo, with a maximum benefit of $15,000 a year.

Odomzo Patient Access Program

This program verifies the patient’s health insurance and outof- pocket costs for Odomzo. Program coordinators will evaluate the patient’s eligibility for financial assistance based on certain medical and financial criteria.

Tazverik (tazemetostat) Tablets

Drug company: Epizyme
833-437-4669

Tazverik is a methyltransferase inhibitor used for the treatment of locally advanced or metastatic epithelioid carcinoma (a type of skin cancer) in patients 16 years or older who are not eligible for surgery.

Epizyme offers 4 financial assistance programs for patients who are prescribed Tazverik:

Co-Pay Assistance Program

With this program, eligible patients who have private insurance will receive copayment assistance to reduce their outof- pocket costs of Tazverik.

Patient Assistance Program

Patients who meet this program’s financial requirements and are uninsured or underinsured may be eligible to receive Tazverik for free for the remainder of the calendar year through this program.

Bridge Supply Program

This program provides an emergency supply of Tazverik for free to eligible patients who have an unexpected disruption in their prescription drug coverage or supply.

QuickStart Program

Eligible patients may be able to receive Tazverik right away if they have a delay of more than 5 days in the authorization of their prescription drug coverage and if their doctor has determined they have to start medical treatment immediately.

Table. Drugs Prescribed for Skin Cancer/Merkel‑Cell Carcinoma

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services


    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment of recurrent locally advanced or metastatic Merkelcell carcinoma, a type of skin cancer

    Treatment of recurrent or metastatic cutaneous squamouscell carcinoma that cannot be cured by surgery or radiation
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400


    Drug name (generic name)
  • Odomzo (sonidegib) Capsules
  • Drug company
  • Sun Pharma
  • Indication
  • Locally advanced basal-cell carcinoma that relapsed after surgery or radiation or cannot be removed by surgery or radiation
  • Patient support services
  • Odomzo Copay Program
    877-636-6961

    Odomzo Patient Access Program
    844-563-6696


Share this:

Last modified: April 8, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country